Page 1 of 12
A Narrative Review and Perspective on Implementation Research on Intradermal Delivery Methods for Fractionated-Dose Inactivated Poliomyelitis Vaccine
Recent trends in intradermal (ID) vaccination, as seen in the Global Polio Eradication Initiative and in the 2022 monkeypox (mpox) pandemic, are a reminder that vaccine administration to the dermis is a valuable alternative to the traditional routes of parenteral delivery.
May 13, 2026
Published Review Highlights Advantages of Needle-free Intradermal Delivery Over Traditional Needle and Syringe
GOLDEN, Colo. — May 19, 2026 — A growing emphasis on dose-sparing strategies and equitable vaccine access has renewed global interest in ID vaccine delivery. A recent, peer-reviewed publication in Qeios¹ evaluated the evidence on implementation of novel technologies for ID delivery of fractional-dose inactivated polio vaccine (fIPV).
May 8, 2026
PharmaJet® Tropis® Needle-free Injection System Selected to Deliver 1.4 Million Polio Vaccine Doses in Nigeria
GOLDEN, Colo. — May 7, 2026 — PharmaJet, a global leader in needle-free injection technology, today announced that its WHO-prequalified Tropis ID Needle-free Injection System will be used to deliver approximately 1.4 million doses of fractional inactivated polio vaccine (fIPV) during upcoming polio immunization campaigns in Nigeria. PharmaJet is partnering with the African Field Epidemiology Network (AFENET), to deploy Tropis for fIPV delivery to children under 5 years of age in Sokoto, a state in northwestern Nigeria.
May 5, 2026
Brazilian Tuberculosis Research Network to Evaluate PharmaJet® Needle-free Tropis® ID Injection Device as Delivery System for Tuberculin Skin Test
GOLDEN, Colo. — March 24, 2026 — PharmaJet®, a company focused on improving the performance and outcomes of injectables through needle-free injection technology, announced that its partner, Brazilian Tuberculosis Research Network (REDE-TB), plans to initiate a clinical study to evaluate the accuracy, workflow efficiency, safety, and acceptability of the tuberculin skin test (TST) using PharmaJet’s Tropis® ID Needle-free Injection System, compared to TST administered by needle.
Tags: Tropis, Tuberculosis
March 20, 2026
Protecting children without fear: A new way to vaccinate against polio in Afghanistan
On a cloudy early morning in Afghanistan’s Laghman province, Dr Arsala set out for Alingar—a rugged, mountain-wrapped district he had visited many times before. After 12 years as a Provincial Polio Officer, he knew the rhythm of polio campaigns: the early starts, the long drives, the predictable challenges. But this time felt unusually different. This time, he carries a new tool being introduced for the first time in Afghanistan’s polio programme.
January 20, 2026
PharmaJet’s Needle-free Injection System Selected to Administer DNA Immunotherapy for Advanced Melanoma in Late-stage Clinical Development following Positive Phase 2 Data
GOLDEN, Colo. — January 9, 2026 — PharmaJet®, a company focused on improving the performance and outcomes of injectables through needle-free injection technology, announced that its partner Scancell has reported updated Phase 2 clinical data from the SCOPE study in unresectable advanced melanoma. In this study, Scancell’s iSCIB1+ immunotherapy was delivered intramuscularly using Stratis, PharmaJet’s Needle-free Injection System. Data was presented at the ESMO Immuno-Oncology Congress 2025 on December 11, 2025.
Tags: Cancer, DNA, Melanoma, Stratis
January 7, 2026
Evaluation of the safety and immunogenicity of two fractional intradermal regimens of MVA-BN compared to standard dose vaccination
Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN) vaccine is being used to mitigate disease in the current global mpox outbreak, but a global vaccine shortage may limit large scale vaccination.
Why Delivery Matters for Pandemic Readiness
Recent crises have shown that pandemics don’t simply strain health systems—they disrupt entire societies. Supply chains falter under global demand. Regulatory processes slow when speed is most vital. Health systems run short on qualified vaccinators. And affordability barriers delay access in the communities that need protection first.
December 10, 2025
Infectious Disease
Needle-free Delivery for Infectious Disease For decades, most vaccines have been delivered intramuscularly using needles. But is this the most effective approach? Intradermal (ID) delivery engages both the cellular and humoral arms of the immune system, often resulting in a stronger, longer-lasting immune response.1 Why Needle-free ID? Needle-free further enhances access and coverage—while eliminating the...
November 16, 2025
Intradermal
Understanding the Skin: A Complex Immune Interface The skin plays a dual role in immune defense — it is the first physical barrier against pathogens and plays a critical role in activating the body’s adaptive immune response. The Skin’s Three Layers1,2 Epidermis: The outermost layer serves as a physical barrier and houses specialized immune cells,...
November 14, 2025
Presentations
Presentations World Vaccine Congress 2025 World Ethiopia 61st Annual Medical Conference
November 11, 2025
PharmaJet® Signs Distribution Agreement with EVA Pharma to Provide Needle-free Injection Systems to Support Routine Polio Immunization in Egypt
GOLDEN, Colo., CAIRO, Egypt — November 6, 2025 — PharmaJet®, a company that strives to improve the performance and outcomes of injectables with its enabling needle-free injection technology, today announced that it has signed a Distribution Agreement with ATR, an affiliate to EVA Pharma, the leading pharmaceutical company driving healthcare innovation and access across the Middle East and Africa. The agreement, signed in Frankfurt at the CPHI meeting on October 30, 2025, includes provisions for Tropis® distribution, technology transfer, and manufacturing.
November 4, 2025
PharmaJet® to Present Latest Results of its Intradermal Programs at American Society of Tropical Medicine and Hygiene Annual Meeting
GOLDEN, Colo. — November 4, 2025 — PharmaJet®, a company that strives to improve the performance and outcomes of injectables with its needle-free injection technology, will present at the American Society of Tropical Medicine and Hygiene (ASTMH) Annual Meeting, November 9-13, at the Metro Toronto Convention Centre in Toronto, Ontario, Canada. The meeting brings together the largest international scientific organization of experts dedicated to reducing the worldwide burden of tropical infectious diseases and improving global health. PharmaJet will share why an increasing number of drug developers are exploring the benefits that Tropis intradermal delivery brings to their injectable product development programs.
Tags: Events, Polio, Tropis, Tuberculosis
October 29, 2025
PharmaJet® Tropis® Needle-free Injection System selected for Polio Immunization Campaign in Pakistan
GOLDEN, Colo. — October 23, 2025 — PharmaJet®, a company that strives to improve the performance and outcomes of injectables with its innovative needle-free injection technology, today announced that their WHO prequalified Tropis ID Needle-free Injection System will be used in the latest polio immunization campaign in Pakistan, planned for late 2025.
October 6, 2025
PharmaJet® to Highlight the Benefits of Intradermal Needle-free Delivery and Expansion into the Self-Injection Pen Market at Upcoming PODD Conference
GOLDEN, Colo. — October 21, 2025 — PharmaJet®, a company that strives to improve the performance and outcomes of injectables with its needle-free injection technology, will present at the 15th Annual Partnership Opportunities in Drug Delivery (PODD) conference, October 27-28, at Westin Copley Place in Boston, Massachusetts. The conference brings together representatives from the pharmaceutical, biotech, and drug delivery industries to assess delivery needs, explore partnership opportunities, and stay at the forefront of innovative drug delivery technologies. PharmaJet will share why an increasing number of drug developers are exploring the benefits that Tropis intradermal delivery brings to their injectable product development programs.
Tags: Events, Self-injector pen, Subcutaneous, Tropis
PharmaJet®, a World Leader in Needle-free Injection Systems, is Initiating the Development of Needle-free Self-Injection Pens for Home Use
GOLDEN, Colorado — October 7, 2025 — PharmaJet®, a company that strives to improve the performance and outcomes of injectables with its enabling needle-free injection technology, today announced that it is expanding its needle-free injection portfolio with the development of a suite of proprietary, needle-free, self-injector pens. Prototypes of the subcutaneous (SC) injectors, aimed at the chronic disease and metabolic peptide self-injection markets, are currently in early testing.
Tags: Disposable, Other, Self-injector pen, Subcutaneous
October 1, 2025
Ministry of Public Health Launches fIPV & OPV Campaign in Eastern Afghanistan
Kabul, 30 August 2025 – The Ministry of Public Health of Islamic Emirate of Afghanistan has launched a combined fractional Inactivated Polio Vaccine (fIPV) and Oral Polio Vaccine (OPV) campaign in the eastern region of the country, covering Nangarhar, Kunar, Laghman, and Nuristan provinces.
September 3, 2025
Unlocking the Full Potential of Immunization: The Case for Intradermal Delivery
Successful immunization depends not only on the antigen used but also on how and where it is delivered. Most vaccines and therapeutic injectables today are administered via subcutaneous (SC) or intramuscular (IM) routes. These routes have become standard, but are they the most effective?
August 25, 2025
Intradermal Polio Vaccination Initiatives
PharmaJet has secured a contract to facilitate the inaugural major deployment of an intradermal polio vaccination initiative in Afghanistan, utilizing its Tropis needle-free delivery mechanism. This development is an extension of the system’s prior application in analogous public health endeavors across Pakistan, Nigeria, and Somalia.
Page 1 of 12